[go: up one dir, main page]

AR039703A1 - Composiciones nasales - Google Patents

Composiciones nasales

Info

Publication number
AR039703A1
AR039703A1 ARP030102157A ARP030102157A AR039703A1 AR 039703 A1 AR039703 A1 AR 039703A1 AR P030102157 A ARP030102157 A AR P030102157A AR P030102157 A ARP030102157 A AR P030102157A AR 039703 A1 AR039703 A1 AR 039703A1
Authority
AR
Argentina
Prior art keywords
nasal
mucopolysaccharide
active substance
composition according
nasal compositions
Prior art date
Application number
ARP030102157A
Other languages
English (en)
Original Assignee
Novartis Consumer Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Consumer Health Sa filed Critical Novartis Consumer Health Sa
Publication of AR039703A1 publication Critical patent/AR039703A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas adecuadas para administración nasal. Las formulaciones nasales de la presente se caracterizan, entre otras cosas, por tener excelente propiedades humectantes, y por no requerir de un conservador. Reivindicación 1: Una composición farmacéutica nasal que comprende: a) cuando menos una sustancia activa adecuada para administración nasal; b) un mucopolisacárido; y c) propilenglicol. Reivindicación 3: Una composición de acuerdo con la reivindicación 1, en donde la sustancia activa (a) es xilometazolina o una sal nasalmente aceptable de la misma. Reivindicación 5: Una composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, en donde el mucopolisacárido (b) es sulfato de condroitina.
ARP030102157A 2002-06-20 2003-06-18 Composiciones nasales AR039703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02013693 2002-06-20

Publications (1)

Publication Number Publication Date
AR039703A1 true AR039703A1 (es) 2005-03-09

Family

ID=29797130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102157A AR039703A1 (es) 2002-06-20 2003-06-18 Composiciones nasales

Country Status (12)

Country Link
US (1) US20050129622A1 (es)
EP (1) EP1517673A1 (es)
JP (1) JP2005533076A (es)
AR (1) AR039703A1 (es)
AU (1) AU2003278962B2 (es)
CA (1) CA2489528A1 (es)
NO (1) NO20050215L (es)
NZ (1) NZ537186A (es)
PL (1) PL373033A1 (es)
RU (1) RU2005101331A (es)
TW (1) TW200402307A (es)
WO (1) WO2004000272A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094937A1 (en) * 2002-05-09 2003-11-20 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE20318634U1 (de) 2003-11-13 2004-02-26 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
FR2901706A1 (fr) * 2006-06-01 2007-12-07 Persee Medica Soc Par Actions Compositions nasale et buccale pour lutter contre le ronflement
FR2901705A1 (fr) * 2006-06-01 2007-12-07 Persee Medica Soc Par Actions Composition pour lutter contre le ronflement se presentant sous la forme d'un spray nasal
DE102007006122A1 (de) * 2007-02-02 2008-08-07 Krewel Meuselbach Gmbh Cistusextrakte
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
SG11201601625UA (en) 2013-09-11 2016-04-28 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
CN111278425B (zh) * 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945636A1 (de) * 1979-11-12 1981-05-21 Sandoz-Patent-GmbH, 7850 Lörrach Stabile loesungen von hydrierten ergotalkaloiden bzw. ihren salzen und heparin bzw. seinen salzen sowie verfahren zu deren herstellung
US4402949A (en) * 1979-11-12 1983-09-06 Sandoz Ltd. Stable solutions of hydrogenated ergotalkaloids
WO1991012808A1 (en) * 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
JPH10231243A (ja) * 1997-02-20 1998-09-02 Sekisui Chem Co Ltd 粘膜炎症外用薬
JP2001524108A (ja) * 1997-04-30 2001-11-27 ワーナー−ランバート・カンパニー 局所経鼻抗炎症組成物
JPH1179994A (ja) * 1997-09-08 1999-03-23 Ikeda Mohandou:Kk 点鼻適用製剤
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
KR20060066753A (ko) * 1997-10-22 2006-06-16 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
IL136591A (en) * 1998-01-30 2005-08-31 Novartis Consumer Health Sa Nasal pharmaceutical solutions
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
CN1164271C (zh) * 1999-06-22 2004-09-01 贝林格尔·英格海姆国际有限公司 稳定的丁苄唑啉和氧甲唑啉溶液
JP2001072605A (ja) * 1999-09-03 2001-03-21 Lion Corp 経皮経粘膜吸収促進剤組成物
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
WO2002024116A1 (en) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea

Also Published As

Publication number Publication date
PL373033A1 (en) 2005-08-08
TW200402307A (en) 2004-02-16
JP2005533076A (ja) 2005-11-04
NO20050215L (no) 2005-01-13
EP1517673A1 (en) 2005-03-30
AU2003278962C1 (en) 2004-01-06
AU2003278962B2 (en) 2006-11-23
AU2003278962A1 (en) 2004-01-06
CA2489528A1 (en) 2003-12-31
WO2004000272A1 (en) 2003-12-31
NZ537186A (en) 2006-10-27
US20050129622A1 (en) 2005-06-16
RU2005101331A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
AR039703A1 (es) Composiciones nasales
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
BR0016879A (pt) Métodos para transferência de interleucina-2 por via pulmonar
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
BRPI0415020A (pt) dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
AR109357A2 (es) Composición farmacéutica parenteral con tolerancia en el sitio de inyección
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
BRPI0412502A (pt) derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
BR0012696A (pt) Composição oftálmica
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
ATE521349T1 (de) Antimykotische medizinische zusammensetzungen
AR059113A1 (es) Composicion para administracion topica
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
PE20061418A1 (es) Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo
SV2001000093A (es) Formas polimorfas de un citrato de azobiciclo 2,2,2, octan-3-amina y sus composiciones farmaceuticas ref.pcl0216/82962/bb
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal